P920. Breast cancer with more than 3 positive nodes: adjuvant epirubicin followed by CMF +/- hormonotherapy. Preliminary results
A. De Matteis(Università Cattolica del Sacro Cuore), Alfonso Maiorino(Ospedale Monaldi), V. Labonia, Francesco Nuzzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), P. Frezza, M. Elmo, D. Momedoro, G.D.' Aiuto, Rimisha Thomas, Ferdinando Riccardi(Ospedale Antonio Cardarelli), G. Landi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Chiara Longo
Cited by 0
Related Papers
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
|International Journal of Molecular Sciences|2020|194
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180
Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors
|The Oncologist|2014|103